Exagen (XGN) Stock Analysis & AI Equity Report
Exagen (XGN) overview
Exagen (XGN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 66.6m and operating profit of USD -14.1m; the year-end share price was 6.08 USD and market capitalisation was USD 139m. Exagen is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Exagen's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Exagen
Exagen Inc. develops and commercializes AVISE-branded testing products for the diagnosis, prognosis, and monitoring of rheumatic and autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. Its AVISE CTD test supports evaluation of patients with symptoms associated with connective tissue diseases. The company’s tests are used in clinical settings by rheumatologists, primary care physicians, other specialists, and the patients they serve.
Generate the Exagen report
Exagen is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Exagen and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Exagen
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.